Table 2 Differences between patients with FID and AID
Baseline Characteristics | FID n = 88/599 (14.7%) | AID n = 186/599 (31.1%) | P-value |
|---|---|---|---|
Age (mean ± SD, range) | 62.9 ± 13.9 (18–87) | 60.9 ± 15.8 (16–86) | p = 0.310 |
Sex | |||
Female | 42 (47.7%) | 137 (73.3%) | p < 0.001 |
Cancer location | p < 0.000 | ||
Breast | 12 (13.6%) | 74 (39.6%) | 1 |
Genitourinary | 14 (15.9%) | 18 (9.6%) | |
Sarcoma | 16 (18.2%) | 13 (7%) | |
Gastrointestinal | 10 (11.4%) | 23 (12.3%) | |
Thyroid | 6 (6.8%) | 19 (10.2%) | |
Gynaecologic | 10 (11.4%) | 16 (8.6%) | |
Hematologic | 6 (6.8%) | 6 (3.2%) | |
Others | 3 (3.4%) | 9 (4.8%) | |
Melanoma | 6 (6.8%) | 6 (3.2%) | |
Lung | 5 (5.7%) | 3 (1.6%) | |
Cardiovascular risk factors | |||
Hypertension | 29 (32.9%) | 81 (43.5%) | p = 0.11 |
Diabetes | 12 (13.6%) | 29 (15.6%) | p = 0.02 |
Dyslipidaemia | 6 (6.8%) | 24 (12.9%) | p = 0.142 |
Smoking | 21 (23.9%) | 31 (16.7%) | p = 0.6 |
Elevated BNP | 76 (89.4%) | 142 (75.9%) | p = 0.01 |
LVEF (mean ± SD, range, %) | 56.5 ± 11.3 (22–85) | 58.2 ± 10.4 (21–80) | p = 0.226 |
LVEF < 50% | 19 (22.1%) | 24 (13%) | p = 0.03 |
Kidney dysfunction | |||
GFR < 60 ml/min/1.73 m2 | 68 (77.3%) | 139 (74.3%) | p = 0.598 |
TSAT (mean ± SD, range, %) | 13.7 ± 3.8 (4.0–19.0) | 13.5 ± 4.2 (3.0–19.0) | p = 0.707 |
Median | 14 | 14 | |
Ferritin (μg/L) (mean ± SD, range) | 311.5 ± 274.5 (100.0–1468.0) | 37.8 ± 23.7 (6.0–99.0) | p < 0.001 |
Median | 220.5 | 31.5 | |
Serum iron | |||
(umol/L)(mean ± SD, range) | 8.6 ± 7.8 (1.6–76) | 9.55 ± 3.1 (1.6–17) | p = 0.264 |
Anemia | 62 (70.4%) | 82 (45.8%) | p = 0.03 |
Deceased during the study period | 45 (51.1%) | 44 (23.5%) | p < 0.001 |